ABSTRACT
Background Preeclampsia, a pregnancy-specific condition associated with new-onset hypertension after 20 weeks gestation, is a leading cause of maternal and neonatal morbidity and mortality. Predictive tools to understand which individuals are most at risk are needed.
Methods We identified a cohort of N=1,125 pregnant individuals who delivered between 05/2015-05/2022 at Mass General Brigham hospitals with available electronic health record (EHR) data and linked genetic data. Using clinical EHR data and systolic blood pressure polygenic risk scores (SBP PRS) derived from a large genome-wide association study, we developed machine learning (xgboost) and linear regression models to predict preeclampsia risk.
Results Pregnant individuals with an SBP PRS in the top quartile had higher blood pressures throughout pregnancy compared to patients within the lowest quartile SBP PRS. In the first trimester, the most predictive model was xgboost, with an area under the curve (AUC) of 0.73. Adding the SBP PRS to the models improved the performance only of the linear regression model from AUC 0.70 to 0.71; the predictive power of other models remained unchanged. In late pregnancy, with data obtained up to the delivery admission, the best performing model was xgboost using clinical variables, which achieved an AUC of 0.91.
Conclusions Integrating clinical and genetic factors into predictive models can inform personalized preeclampsia risk and achieve higher predictive power than the current practice. In the future, personalized tools can be implemented in clinical practice to identify high-risk patients for preventative therapies and timely intervention to improve adverse maternal and neonatal outcomes.
Competing Interest Statement
KJG has served as a consultant to Illumina Inc., Aetion, Roche, and BillionToOne outside the scope of the submitted work. VPK reports consulting fees from Avania CRO unrelated to the current work and patent #WO2021119593A1 for control of a therapeutic delivery system which is assigned to the Mass General Brigham.
Funding Statement
KJG reports funding from NIH/NHLBI grants K08 HL146963, K08 HL146963-02S1, R01 HL163234-01, R03HL162756-01, and a PJP Grant from the Preeclampsia Foundation. VPK reports funding from NIH/NHLBI grants K08 HL161326-01A1, the Foundation for Anesthesia Education and Research (FAER), Anesthesia Patient Safety Foundation (APSF), Partners Innovation, Brigham Research Institute, Connors Center IGNITE Award, and Brigham Ignite Innovation Award. RS reports funding from NIH/NHLBI grant R01 HL163234-01, and a PJP Grant from the Preeclampsia Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by Mass General Brigham Institutional Review Board, with waiver of patient consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Co-first authors
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request and based on institutional guidelines.
NON-STANDARD ABBREVIATIONS AND ACRONYMS
- AUC
- area under the receiver operator curve
- BMI
- body mass index
- DBP
- diastolic blood pressure
- GWAS
- genome-wide association study
- IUGR
- intrauterine growth restriction
- PCA
- principle components of ancestry
- PRS
- polygenic risk score
- SBP
- systolic blood pressure
- SGA
- small for gestational age
- SNP
- single-nucleotide polymorphism
- XGB
- xgboost
